CORONA REMEDIES LT...● IPO DETAIL GMP+₹290 STATUSListed IPOCloudTrack Every IPO CORONA REMEDIES LT...● IPO DETAIL GMP+₹290 STATUSListed IPOCloudTrack Every IPO
Live GMP
Back to IPOs
Corona Remedies Ltd. Address

Corona Remedies Ltd. Address

NSE & BSE · Mainboard IPO
Listed NSE & BSE Mainboard Live Chart
Issue Price
₹1,062
₹1,062
GMP (Grey Market)
+₹290
+27.31%
Est. Listing Price
₹1,352
Based on GMP
Min. Investment
₹14,868
1 lot × 14 shares
Subscribed
1.00x
Over-subscribed
IPO Details
Open Date
08 Dec 2025
Close Date
10 Dec 2025
Allotment
11 Dec 2025
Listing Date
15 Dec 2025
Exchange
NSE & BSE
Price Band
₹1,062
Listing Price
See chart
Allotment Status
Price Band
₹1,062
Per share
Face Value
₹10 per share
 
Lot Size
14 Shares
per lot
Issue Size
61,71,101 shares (aggregating up to ₹655.37 Cr)
Total offering
Issue Type
Bookbuilding IPO
 
Min Investment
₹14,868
1 lot
Pre-IPO Holding
6,11,60,088 shares
Promoters
Post-IPO Holding
6,11,60,088 shares
Promoters
P/E (Pre)
43.47x
 
P/E (Post)
35.15x
 
EPS (Pre)
₹24.43
 
EPS (Post)
₹30.21
 
UPI Deadline
2025-12-10
Mandate
GMP
+₹290
+27.31% est.
Anchor AllotmentSun, 07 Dec 2025
Basis of AllotmentThu, 11 Dec 2025
Refund InitiationFri, 12 Dec 2025
Demat CreditFri, 12 Dec 2025
Listing DayMon, 15 Dec 2025
UPI Mandate Deadline2025-12-10
Sale TypeOffer For Sale
QIB Quota50% of Net Issue
HNI / NII Quota15% of Net Issue
Retail Quota35% of Net Issue
Check AllotmentClick here →
Subscription Rate Final
Corona Remedies Ltd. Address IPO subscribed 1.00 times overall. Retail: 1.00x. QIB: 1.00x. NII: 1.00x. By 10 Dec 2025.
QIB
1.00x
Over
NII/HNI
1.00x
Over
Retail
1.00x
Over
Total
1.00x
Over
Category Subscription Shares Offered % of Total Amount (₹Cr)
QIB
Over 1.00x
NII / HNI
Over 1.00x
Retail
Over 1.00x
Total 1.00x
6,171,102
100% ₹655.37
IPO Shares Offered
Corona Remedies Ltd. Address IPO total issue size: ₹655.37 Cr.
CategoryShares OfferedAmount (₹Cr)Size (%)
Total 6,171,102 ₹655.37
100.00%
* Based on upper price band ₹1,062 per share
Lot Size & Investment
Lot Size
14
Shares per Lot
Issue Price
₹1,062.00
Upper Band
Min Investment
₹14,868
1 Lot
ApplicationLotsSharesAmount
Retail (Min — 2 Lots)228₹29,736
Retail (Max — 13 Lots)13182₹193,284
S-HNI (Min — 14 Lots)14196₹208,152
B-HNI (Min — 68 Lots)68952₹1,011,024
* Issue Price ₹1,062 × Lot Size 14 shares
IPO Schedule
Anchor
07 Dec 2025
✓ Done
IPO Open
08 Dec 2025
✓ Done
IPO Close
10 Dec 2025
✓ Done
Allotment
11 Dec 2025
✓ Done
Refunds
12 Dec 2025
✓ Done
Demat Credit
12 Dec 2025
✓ Done
Listing Day
15 Dec 2025
✓ Done
Corona Remedies Ltd. Address — Live Price LIVE
₹1,062.00
INR · BSE
Fetching…
vs Issue Price
OPEN
HIGH
LOW
MKT CAP
P/E
52W HIGH
52W LOW
VOLUME
DIVIDEND
DIV YIELD
Loading…
Chart Not Available
Try again 2–3 days after listing.
Issue ₹1,062.00 GMP: +₹290 Live Price
About Corona Remedies Ltd. Address
Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.The company has two manufacturing facilities, located in the states of Gujarat with an aggregate installed capacity for formulations of 1,285.44 million units per annum.Competitive Strength:Second fastest growing company in the top 30 Indian pharmaceutical companies by domestic sales from MAT June 2022 to MAT June 2025, well-positioned to seize opportunities in the Indian market.Demonstrated capabilities of building a diversified portfolio, including “engine” brands, in our targeted therapy areas.Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.Qualified, experienced and entrepreneurial management team supported by marquee investors.
Objects of the Issue
1
BRLMs fees and commissions (including underwriting commission, brokerage and selling commission)
2
Fees payable to the Registrar to the Offer
3
Selling commission/processing fee for SCSBs and Bankers to the Offer, fee payable to the Sponsor Bank(s) for Bids made by RIIs using UPI, brokerage and selling commission and bidding charges for the Members of the Syndicate, Registered Brokers, RTAs and CDPs
4
Advertising and marketing expenses
5
Others: Listing fees, SEBI filing fees, upload fees, BSE and NSE processing fees, book building software fees
6
Other regulatory expenses
7
Fees payable to legal counsels, statutory auditors, independent chartered accountants, practising company secretary, intellectual property consultants, industry service provider and others
8
Printing and distribution of issue stationery
9
Miscellaneous
Corona Remedies Ltd. Address Financials (Amount in ₹ Crore)
Revenue from Operations
₹1,020.9
31 Mar 2024
₹1,202.4
31 Mar 2025
₹348.6
30 Jun 2025
Profit After Tax (PAT)
₹90.5
31 Mar 2024
₹149.4
31 Mar 2025
₹46.2
30 Jun 2025
Particulars30 Jun 202531 Mar 202531 Mar 2024
Revenue from Operations 348.56 1202.35 1020.93
EBITDA 71.80 245.91 161.19
Profit After Tax (PAT) 46.20 149.43 90.50
Net Worth 607.02 606.34 480.41
Total Assets 1012.38 929.86 830.58
Reserves & Surplus 545.86 545.18 419.25
Borrowings 106.65 62.70 134.14
EBITDA Margin (%) 20.55%
PAT Margin (%) 12.49%
P/BV Ratio
10.71
RoE
27.50%
RoCE
41.32%
RoNW
24.65%
PAT Margin
12.49%
EBITDA Margin
20.55%
Debt/Equity
0.10
Issue Structure & Shareholding
Total Shares Offered61,71,102 (100.00%)
Net Offer to PublicN/A
Reserved for Market MakerN/A
Pre-Issue Promoter Holding6,11,60,088 shares
Post-Issue Promoter Holding6,11,60,088 shares
P/BV Ratio10.71
RoE27.50%
RoCE41.32%
Debt / Equity0.10
Script CodeN/A
Registrar & Lead Managers
Book Running Lead Managers
JM Financial Ltd.
IIFL Capital Services Ltd
Kotak Mahindra Capital Co.Ltd
GMP Disclaimer: Grey Market Premium data is unofficial and unregulated. It does not guarantee actual listing price.
IPO Subscription FAQs
How much Corona Remedies Ltd. Address IPO subscribed?

Corona Remedies Ltd. Address IPO is subscribed 1.00 times by Dec 10, 2025. Retail: 1.00x. QIB: 1.00x. NII: 1.00x.

Investor CategorySubscription
Qualified Institutional (QIB)1.00x
Non Institutional (NII/HNI)1.00x
Retail Individual1.00x
Total Subscription1.00x
What is Corona Remedies Ltd. Address IPO retail subscription status?

The Corona Remedies Ltd. Address IPO retail category is subscribed 1.00 times as of 10 Dec 2025. The retail portion is oversubscribed.

How to subscribe Corona Remedies Ltd. Address IPO?

Subscribe via your broker app using ASBA or UPI. Opens 08 Dec 2025 and closes 10 Dec 2025. Min investment: ₹14,868 (1 lot = 14 shares). UPI mandate: 2025-12-10.

How many times Corona Remedies Ltd. Address IPO subscribed?

The Corona Remedies Ltd. Address IPO subscribed 1.00x overall. QIB: 1.00x, NII: 1.00x, Retail: 1.00x. Applications: from NSE/BSE.

How to check Corona Remedies Ltd. Address IPO allotment?

Check allotment on the registrar website (Bigshare Services Pvt.Ltd) at https://ipo.bigshareonline.com/IPO_Status.html. Enter your PAN, application number or DP/Client ID. Allotment date: 11 Dec 2025. Refunds: on 12 Dec 2025.

When Corona Remedies Ltd. Address IPO will be listed?

The Corona Remedies Ltd. Address IPO listing date is 15 Dec 2025, Monday. Listed on: NSE & BSE. Issue price: ₹1,062. Estimated listing: ₹1,352. GMP: +₹290.

When Corona Remedies Ltd. Address IPO close?

The Corona Remedies Ltd. Address IPO closes on 10 Dec 2025, Wednesday. UPI mandate: 2025-12-10. Allotment: 11 Dec 2025. Listing: 15 Dec 2025.